Menu
← Oncology Approval Tracker
FDA DECISION ·
Imbruvica + rituximab
ibrutinib + rituximab · Pharmacyclics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults receiving initial treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma.
LAMPGEN ANALYSIS
Why it matters
Added a BTK inhibitor plus anti-CD20 regimen for first-line care.
What research teams should watch
Coordinate oral adherence monitoring with infusion visits and verify bleeding-risk medications.
PRIMARY RECORDS